C Garbe1, U Keim1, T K Eigentler1, T Amaral1,2, A Katalinic3, B Holleczek4, P Martus5, U Leiter1. 1. Centre for Dermato-Oncology, Department of Dermatology, Eberhard-Karls University, Tuebingen, Germany. 2. Portuguese Air Force Health Care Direction, Lisbon, Portugal. 3. Institute of Social Medicine and Epidemiology, University Hospital Schleswig-Holstein, Luebeck, Germany. 4. Saarland Cancer Registry, Saarbruecken, Germany. 5. Institute for Clinical Epidemiology und Applied Biostatistics, Eberhard-Karls University, Tuebingen, Germany.
Abstract
OBJECTIVES: To characterize incidence and mortality trends of cutaneous melanoma (CM) in Germany to extrapolate these data until 2030. METHODS: We evaluated data from the Centre for Cancer Registry Data (1999-2012) and from the Saarland Cancer Registry (1970-2012). Age-standardized (according to the European Standard Population, WHO 1976) incidence and mortality rates [age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs)] and crude incidence and mortality rates [crude incidence rates (CIRs) and crude mortality rates (CMRs)] were analysed. RESULTS: In entire Germany, ASIRs increased by 55% to 19.2 and CIRs by 77% to 26.0 new cases per 100 000 from 1999 to 2012. ASMRs remained stable, whereas CMR increased by 58% to 4.1 for males and by 30% to 3.0 for females per 100 000. In the Federal State of Saarland, ASIRs increased more than four-fold to 13.1, CIRs increased six-seven fold to 18.5/100 000 from 1970 to 2012. In the same period, ASMRs increased three-fold in males and two-fold in females to 2.5 and 1.6, whereas CMRs increased 5.5-fold in males and 3.5-fold in females to 3.9 and 3.2/100 000, mainly caused by steep increases of CIRs and CMRs in age groups ≥60 years. Projected CIRs will rise to 44-46 for males and 38-40 for females in 2030. Steepest increases were extrapolated for patients ≥60 years, especially for males, but are also expected for age groups of 40-59 years. In contrast, CIRs are anticipated to stabilize for subjects <40 years. CONCLUSIONS: There is a constant increase in incidence and mortality rates for CM in Germany. As the German population is ageing and the current population has already accumulated high levels of UV exposure, a further increase in melanoma incidence is projected for the future without signs of levelling-off.
OBJECTIVES: To characterize incidence and mortality trends of cutaneous melanoma (CM) in Germany to extrapolate these data until 2030. METHODS: We evaluated data from the Centre for Cancer Registry Data (1999-2012) and from the Saarland Cancer Registry (1970-2012). Age-standardized (according to the European Standard Population, WHO 1976) incidence and mortality rates [age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs)] and crude incidence and mortality rates [crude incidence rates (CIRs) and crude mortality rates (CMRs)] were analysed. RESULTS: In entire Germany, ASIRs increased by 55% to 19.2 and CIRs by 77% to 26.0 new cases per 100 000 from 1999 to 2012. ASMRs remained stable, whereas CMR increased by 58% to 4.1 for males and by 30% to 3.0 for females per 100 000. In the Federal State of Saarland, ASIRs increased more than four-fold to 13.1, CIRs increased six-seven fold to 18.5/100 000 from 1970 to 2012. In the same period, ASMRs increased three-fold in males and two-fold in females to 2.5 and 1.6, whereas CMRs increased 5.5-fold in males and 3.5-fold in females to 3.9 and 3.2/100 000, mainly caused by steep increases of CIRs and CMRs in age groups ≥60 years. Projected CIRs will rise to 44-46 for males and 38-40 for females in 2030. Steepest increases were extrapolated for patients ≥60 years, especially for males, but are also expected for age groups of 40-59 years. In contrast, CIRs are anticipated to stabilize for subjects <40 years. CONCLUSIONS: There is a constant increase in incidence and mortality rates for CM in Germany. As the German population is ageing and the current population has already accumulated high levels of UV exposure, a further increase in melanoma incidence is projected for the future without signs of levelling-off.
Authors: G H Bernhard; R E Neale; P W Barnes; P J Neale; R G Zepp; S R Wilson; A L Andrady; A F Bais; R L McKenzie; P J Aucamp; P J Young; J B Liley; R M Lucas; S Yazar; L E Rhodes; S N Byrne; L M Hollestein; C M Olsen; A R Young; T M Robson; J F Bornman; M A K Jansen; S A Robinson; C L Ballaré; C E Williamson; K C Rose; A T Banaszak; D -P Häder; S Hylander; S -Å Wängberg; A T Austin; W -C Hou; N D Paul; S Madronich; B Sulzberger; K R Solomon; H Li; T Schikowski; J Longstreth; K K Pandey; A M Heikkilä; C C White Journal: Photochem Photobiol Sci Date: 2020-05-20 Impact factor: 3.982
Authors: Gabriella Liszkay; Zoltan Kiss; Roland Gyulai; Judit Oláh; Péter Holló; Gabriella Emri; András Csejtei; István Kenessey; Angela Benedek; Zoltán Polányi; Zsófia Nagy-Erdei; Andrea Daniel; Kata Knollmajer; Máté Várnai; Zoltán Vokó; Balázs Nagy; György Rokszin; Ibolya Fábián; Zsófia Barcza; Csaba Polgár Journal: Front Oncol Date: 2021-02-12 Impact factor: 6.244
Authors: Annkathrin Hornung; Theresa Steeb; Anja Wessely; Titus J Brinker; Thomas Breakell; Michael Erdmann; Carola Berking; Markus V Heppt Journal: Int J Environ Res Public Health Date: 2021-02-10 Impact factor: 3.390
Authors: Adriana Raquel Rinflerch; Victoria Ines Volonteri; María Cecilia Roude; Laura Vanina Pagotto; Melina Pol; Luis Daniel Mazzuoccolo Journal: An Bras Dermatol Date: 2021-11-17 Impact factor: 1.896
Authors: Sebastian Haferkamp; Christian Apfelbacher; Konstantin Drexler; Hans Drexler; Edward K Geissler; Mark Berneburg Journal: Adv Ther Date: 2021-10-01 Impact factor: 3.845
Authors: Claus Garbe; Ulrike Keim; Stefan Suciu; Teresa Amaral; Thomas K Eigentler; Anja Gesierich; Axel Hauschild; Lucie Heinzerling; Felix Kiecker; Dirk Schadendorf; Rudolf Stadler; Cord Sunderkötter; Thomas Tüting; Jochen Utikal; Uwe Wollina; Christos C Zouboulis; Ulrich Keilholz; Alessandro Testori; Peter Martus; Ulrike Leiter; Alexander M M Eggermont Journal: J Clin Oncol Date: 2020-06-12 Impact factor: 44.544